The U.S. Food and Drug Administration (FDA) has approved the subcutaneous formulation of isatuximab-irfc (Sarclisa Escena) for three multiple myeloma treatment regimens, expanding an anti-CD38 therapy that was previously available only as an intravenous infusion. While the approval offers patients
